San Francisco, 03 January , Liver Diseases Therapeutics Market Analysis
By Product (Antiviral Drugs, Vaccines, Chemotherapy, Targeted Therapy,
Immunosuppressants, Immunoglobulins, Corticosteroids), And Segment Forecasts To
2022
The liver diseases therapeutics market had value over USD
7,498.0 million in 2014. The major driving factors are increasing numbers of
liver diseases like hepatocellular carcinoma and vast unexploited need of
patients with these types of diseases. In addition, increasing geriatric population
globally is estimated to augment the market demand in the future period.
Huge expenditure by biotechnology and
pharmaceutical industries on R&D and availability of sturdy pipeline are
the major expected boosting factors for the growth of liver diseases therapeutics
market in future period. Governments’ and big companies’ vaccination program
are creating awareness about the illness and prevention is boosting the growth
of the market.
The market is bifurcated into products and
regions. New products are rapidly being launched boosting the market growth.
The growth of the market is boosted by the strategic alliances, joint venture
between the major players, and growing awareness of healthcare in the upcoming
nations.
Access Full Research Report On Liver Diseases Therapeutics Market Analysis:
www.grandviewresearch.com/industry-analysis/liver-diseases-therapeutics-market
www.grandviewresearch.com/industry-analysis/liver-diseases-therapeutics-market
Nonetheless, risks and side effects linked
with existing medication & stringent FDA and other norms approved by the
government along with accessibility of varying treatment measures perform as
barriers to the industry. The market was dominated by the antiviral drug sector
with a value over USD 2631 million in revenue terms in 2014.
Rising population with liver diseases due
to increasing number of alcohol consumers is estimated to boost the market
share. Alternatively, the antiviral drug is estimated to observer profitable raise
of over 8.8% from 2015 to 2022. This is due to the occurrence of drugs in the
pipeline.
The market is estimated to be at over USD
12095.0 million by 2022. This is going to happen due to the increasing
geriatric population, rising liver ailments like hepatocellular and hepatitis
carcinoma along with high requirement for programs on vaccination in developing
nations and high spending on growing healthcare in the developed nations.
North America is dominating the global
market due to academic and research institutions performing studies related to
medical trials. North America had more than 39% share of the global market in
2014 and is anticipated to carry on leading till 2022. Asia Pacific had share
over USD 1615.5 million in 2014 and is estimated at CAGR over 8.5% in the
future.
Few of the major industries are Abbott
Laboratories, Gilead Sciences, Astellas Pharma Inc., GlaxoSmithKline plc,
Bristol-Mayers Squibb, and Merck & Co., Inc.
Access Full Press Release of this Report:
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and
consulting company, registered in the State of California and headquartered in
San Francisco. The company provides syndicated research reports, customized
research reports, and consulting services. To help clients make informed
business decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to chemicals,
materials and healthcare.
For more information: www.grandviewresearch.com/
